We report an efficient synthesis of the dimeric trans-epoxyamide chrysamide B, recently isolated from the deep-sea-derived fungus Penicillium chrysogenum SCSIO41001. Our synthetic strategy exploits a convergent approach using solid-phase peptide synthesis for the piperazine core and a Sharpless-Katsuki epoxidation to prepare the chiral epoxyacid. The double amidation final step provides chrysamide B that was thouroughly characterized with all spectra identical to those of the natural sample. The approach was devised to facilitate the preparation of a library of analogs of chrysamide B.
Introduction
Marine microorganisms are well-known sources of novel bioactive natural products (Fig.1) . [1] [2] [3] [4] [5] [6] For example, piperazine derivatives are of particular interest exhibiting anticancer, antiviral, antibacterial, antimalaria, anti-HIV and antifungal activities. 4, 7 Also, the piperazine moiety is widely used as a scaffold in the preparation of bioactive compounds due to its ability to bind multiple receptors with high affinity and to orient divergently two lateral chains.
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Figure 1. Structures of chiral piperazine derivatives isolated from marine microorganisms
In 2016, three new dimeric nitrophenyl trans-epoxyamides, chrysamides A-C, were isolated from the deep-sea-derived fungus Penicillium chrysogenum SCSIO41001. 5, 11 Chrysamides A and B (Fig.  1 ) possess a unique symmetrical dimer skeleton featuring a chiral piperazine central core. Such dimeric natural products are attractive to medicinal chemists due to their pharmacological potential. [11] [12] [13] A preliminary biological screening showed that chrysamide A exhibits inhibitory effect on the production of proinflammatory cytokine IL-17.
11 However, no biological activity has been associated to chrysamide B so far, perhaps due to the lack of sufficient material for biological testing. To further investigate the pharmacological potential of chrysamide B, we have developed a synthetic methodology which gives access rapidly to this unique compound. The main step involves a double amidation of the chiral D-alanine derived 1,4-piperazine ring (2) with the epoxyacid (3) as final step (Fig. 2) . Taking advantage of the availability of Boc protected natural and unnatural amino acids as chiral synthons, the chiral 1,4-piperazine ring (2) was synthesized via diamide reduction of D-alanine 2,5-diketopiperazine derivative (4). Among various possible synthetic strategies to access 2,5-diketopiperazines, we chose a solid-phase synthesis on oxime resin shown in Figure 3 . [14] [15] [16] [17] The first N-Boc-protected D-alanine was coupled for three hours using diisopropylcarbodiimide (DIC) and 6-chloro-hydroxybenzotriazole (6-Cl-HOBt) as coupling reagents. The Boc protecting group was removed using a mixture of 1:1 trifluoroacetic acid (TFA)/ dichloromethane, while the second amino acid was activated with 6-Cl-HOBt and 2-(6-Chloro-1H-benzotriazole-1-yl)-1,1,3,3-tetramethylaminium hexafluorophosphate (HCTU). After coupling and deprotection, the linear dipeptide was simultaneously cyclized and cleaved from the resin in the presence of diisopropylethylamine (DIEA; 2.5 equiv.) and acetic acid (AcOH; 5 equiv.) in dichloromethane, leading very efficiently to 2,5-diketopiperazine 4 (92% yield) without epimerization. Based on work done in our lab, 18 we chose lithium aluminum hydride (1 M in THF) in dry THF under an inert atmosphere as optimal reducing conditions. After 48 hours, sodium sulfate decahydrate was added to neutralize residual lithium aluminum hydride and other active species, and the mixture was refluxed for 30 minutes. 19, 20 A simple filtration eliminated the residual solids and led to the desired D-alanine derived 1,4-piperazine (2) in 74% yield. NMR studies showed 6% epimerization during the overall reduction procedure. 18, 21 The 1,4-piperazine 2 was obtained with an overall yield of 68% in six steps starting from commercially available oxime resin and N-Boc protected Dalanine precursors with the solid-phase peptide synthesis. The separation of the contaminant epimer proved difficult at this stage with the piperazine degrading slowly during chromatography on silica. We decided to use piperazine 2 as is in the next steps and to perform purification on the final product.
Preparation of epoxy-acid 3
The synthesis of key epoxy-acid building block 3 is shown in Figure 4 . It is prepared in four steps from commercially available p-nitrobenzaldehyde. This aldehyde reacted with trietyl-2-phosphonopropionate in the presence sodium hydride in a Horner-Wadsworth-Emmons olefination 22, 23 to obtain the cinnamate derivative 5. The ester 5 was then reduced with DIBAL at -78 o C in dichloromethane giving the allylic alcohol 6. [23] [24] [25] We envisioned that the epoxy-alcohol could be prepared in a highly enantioselective fashion by a Sharpless-Katsuki epoxidation reaction on the tri-substituted alkene 6. 25 Several experiments led to the optimal conditions. During our exploration of the allyl alcohol epoxidation, we observed lower chemical yields and enantioselectivities when employing diethyl tartrate ((-)-DET). Better results were obtained with titanium isopropoxide Ti(O i Pr)4 and diisopropyl tartrate ((-)-DIPT). We tried increasing from 5 mol% and 7.5 mol% to 10 and 15 mol% of Ti(O i Pr)4 and (-)-DIPT respectively to verify the impact on yield and enantioselectivity of the corresponding epoxy-alcohol 7. The best yield was obtained with the latter conditions at -23 o C providing enantioselectivity of 98% with the desired stereochemistry, in agreement with Sharpless proposed mechanism. [26] [27] [28] The enantiomeric excess was determined by HPLC analysis using a chiral AD-H column by comparison with the other enantiomer obtained using the same epoxidation conditions but with (+)-DIPT. 21 The synthesis of the key epoxy-acid 3 was then achieved using first 2,2,6,6-tetramethylpiperidine 1-oxyl (TEMPO) and sodium hypochlorite (NaOCl) to convert the epoxy-alcohol to epoxy-aldehyde without purification as green procedure. 29 The crude product was further treated with sodium chlorite (NaOCl2), sodium dihydrogenophosphate (NaH2PO4) and 2-methylbut-2-ene. 25, 30 Simple acid-base extractions gave the pure epoxy-acid 3. It is noteworthy of mention, oxidation of the primary alcohol with PDC 31 or by a ruthenium catalyzed process 25, 32 provided the desired carboxylic acid in poor yield with significant degradation into undesired side products. Previous examples of related double amidation are reported in the literature using SchottenBaumann reaction, 33 mixed anhydride 32 and peptide coupling agents 34 to assemble carboxylic acids onto 1,4-piperazine secondary amines. Having more experience with peptide coupling agents, we envisioned to assemble piperazine 2 with epoxy-acid 3 by a direct double amidation reaction to yield chrysamide B in one step. The epoxy-acid 3 was converted first to an activated ester in the presence of 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo [4,5-b ]pyridinium 3-oxide hexafluorophosphate (HATU). The piperazine was then added to the reaction mixture to provide chrysamide B. Using two equivalents of 3 (one per secondary amine), conversion of the starting diamine was not complete after 16 hours. However, near complete conversion was observed by increasing the amount of epoxy-acid 3 to 3 equivalents. Under those conditions, chrysamide B was obtained in 70% yield, although with a diastereomeric ratio of 94:6 (cis:trans) as determined by HPLC analysis. HPLC semi-preparative purification afforded enantiopure chrysamide B (see ESI for details). Spectroscopic data of synthetic chrysamide B (1) matched entirely those of the isolated natural product (see ESI for details).
In conclusion, we achieved the first total synthesis of chrysamide B (1) in six steps with an overall yield of 32% taking advantage of solid-phase synthesis of a chiral 2,5-diketopiperazine and the highly enantioselective Sharpless-Katsuki epoxidation reaction. The high convergency of the synthetic methodology paves the way to a rapid access of a wide variety of enantiopure chrysamide analogs with stereocontrol at all chiral centers. Work is currently underway to study the bioactivity of chrysamide B, as well as to prepare its analogs and chrysamide A containing a unique bicyclic bis-hemiaminal structure.
